PROPYLTHIOURACIL (propylthiouracil) by Pfizer is thyroid hormone synthesis inhibitors [moa]. First approved in 1947.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
Propylthiouracil (PTU) is an oral tablet thyroid hormone synthesis inhibitor used to treat hyperthyroidism by blocking thyroid peroxidase and reducing production of T3 and T4. It is a first-generation antithyroid agent with a mechanism of action that disrupts thyroid hormone synthesis at the cellular level. PTU is particularly valued in patients who cannot tolerate methimazole or during early pregnancy due to lower teratogenic risk.
As a legacy oral antithyroid with approaching loss of exclusivity, the brand team is likely small and focused on market defense and transition strategy.
Thyroid Hormone Synthesis Inhibitors
Thyroid Hormone Synthesis Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PTU offers limited growth opportunity as the product approaches LOE and faces significant generic competition; roles are primarily defensive and focused on protecting remaining market share in niche populations. Career advancement is constrained; professionals on this team typically transition to growth-stage assets or business development roles.
Worked on PROPYLTHIOURACIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.